Lib Therapeutics Inc

LIB Therapeutics is a Cincinnati-based biopharmaceutical company focused on developing lerodalcibep, a novel PCSK9 inhibitor for lowering LDL cholesterol. Their mission is to help patients with cardiovascular disease and familial hypercholesterolemia achieve their LDL-C goals through innovative, convenient therapies.